Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ONVO's Cash to Debt is ranked higher than
86% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.62 vs. ONVO: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ONVO' s Cash to Debt Range Over the Past 10 Years
Min: 548.78  Med: 10000.00 Max: 10028.4
Current: No Debt
548.78
10028.4
Equity to Asset 0.92
ONVO's Equity to Asset is ranked higher than
96% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ONVO: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
ONVO' s Equity to Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.92 Max: 0.96
Current: 0.92
-0.32
0.96
F-Score: 4
Z-Score: 37.57
M-Score: -1.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2605.73
ONVO's Operating margin (%) is ranked lower than
94% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.72 vs. ONVO: -2605.73 )
Ranked among companies with meaningful Operating margin (%) only.
ONVO' s Operating margin (%) Range Over the Past 10 Years
Min: -5448.28  Med: -3955.84 Max: -778.53
Current: -2605.73
-5448.28
-778.53
Net-margin (%) -2601.15
ONVO's Net-margin (%) is ranked lower than
94% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.29 vs. ONVO: -2601.15 )
Ranked among companies with meaningful Net-margin (%) only.
ONVO' s Net-margin (%) Range Over the Past 10 Years
Min: -6820.05  Med: -4453.41 Max: -2601.15
Current: -2601.15
-6820.05
-2601.15
ROE (%) -56.50
ONVO's ROE (%) is ranked lower than
74% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. ONVO: -56.50 )
Ranked among companies with meaningful ROE (%) only.
ONVO' s ROE (%) Range Over the Past 10 Years
Min: -120.28  Med: -69.58 Max: -62.04
Current: -56.5
-120.28
-62.04
ROA (%) -52.43
ONVO's ROA (%) is ranked lower than
74% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. ONVO: -52.43 )
Ranked among companies with meaningful ROA (%) only.
ONVO' s ROA (%) Range Over the Past 10 Years
Min: -3700  Med: -77.23 Max: -58.03
Current: -52.43
-3700
-58.03
ROC (Joel Greenblatt) (%) -1182.15
ONVO's ROC (Joel Greenblatt) (%) is ranked lower than
83% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -12.38 vs. ONVO: -1182.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ONVO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11894.96  Med: -2682.13 Max: -1340.94
Current: -1182.15
-11894.96
-1340.94
» ONVO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ONVO Guru Trades in Q2 2015

Paul Tudor Jones 136,040 sh (New)
» More
Q3 2015

ONVO Guru Trades in Q3 2015

Paul Tudor Jones 16,946 sh (-87.54%)
» More
Q4 2015

ONVO Guru Trades in Q4 2015

Paul Tudor Jones 29,779 sh (+75.73%)
» More
Q1 2016

ONVO Guru Trades in Q1 2016

Paul Tudor Jones 29,872 sh (+0.31%)
» More
» Details

Insider Trades

Latest Guru Trades with ONVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:AMEX:SENS, NAS:SRDX, NYSE:ENZ, NAS:TRIB, NAS:NRCIB, NAS:FLDM, NAS:HSKA, NAS:RDNT, OTCPK:CLIFF, NYSE:NVTA, NAS:BEAT, NAS:NVDQ, NAS:QTNT, NAS:OXFD, OTCPK:EPLYF, OTCPK:EDTXF, NYSE:ARA, NAS:TROV, NAS:LNTH, NAS:TTOO » details
Traded in other countries:4OR.Germany, ONVO.Switzerland, 0R02.UK,
Organovo Holdings Inc is a development-stage company. It is engaged in developing and commercializing functional human tissues.

Organovo Holdings Inc is incorporated in Delaware on April 2007. The Company is a development-stage company. It is engaged in developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company intend to introduce a paradigm shift in the approach to the generation of three-dimensional human tissues, by utilizing its proprietary platform technology to create human tissue constructs in 3D that mimic native human tissue composition and architecture. The Company is subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, emissions and wastewater discharges, and the use and disposal of hazardous or potentially hazardous substances used in connection with research, including infectious disease agents.

Ratios

vs
industry
vs
history
P/B 6.42
ONVO's P/B is ranked lower than
75% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.37 vs. ONVO: 6.42 )
Ranked among companies with meaningful P/B only.
ONVO' s P/B Range Over the Past 10 Years
Min: 2.05  Med: 9.69 Max: 63.4
Current: 6.42
2.05
63.4
P/S 254.71
ONVO's P/S is ranked lower than
96% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.37 vs. ONVO: 254.71 )
Ranked among companies with meaningful P/S only.
ONVO' s P/S Range Over the Past 10 Years
Min: 81.92  Med: 385.00 Max: 1744
Current: 254.71
81.92
1744
EV-to-EBIT -8.74
ONVO's EV-to-EBIT is ranked lower than
99.99% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. ONVO: -8.74 )
Ranked among companies with meaningful EV-to-EBIT only.
ONVO' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.6  Med: -7.25 Max: 46.4
Current: -8.74
-25.6
46.4
EV-to-EBITDA -8.93
ONVO's EV-to-EBITDA is ranked lower than
99.99% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.01 vs. ONVO: -8.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
ONVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26  Med: -7.35 Max: 44.8
Current: -8.93
-26
44.8
Current Ratio 14.18
ONVO's Current Ratio is ranked higher than
97% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.89 vs. ONVO: 14.18 )
Ranked among companies with meaningful Current Ratio only.
ONVO' s Current Ratio Range Over the Past 10 Years
Min: 0.36  Med: 10.77 Max: 25.97
Current: 14.18
0.36
25.97
Quick Ratio 14.10
ONVO's Quick Ratio is ranked higher than
97% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ONVO: 14.10 )
Ranked among companies with meaningful Quick Ratio only.
ONVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.36  Med: 10.75 Max: 25.94
Current: 14.1
0.36
25.94
Days Sales Outstanding 63.75
ONVO's Days Sales Outstanding is ranked higher than
50% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.75 vs. ONVO: 63.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
ONVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.4  Med: 56.58 Max: 63.75
Current: 63.75
49.4
63.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.10
ONVO's Price/Net Cash is ranked higher than
56% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.51 vs. ONVO: 7.10 )
Ranked among companies with meaningful Price/Net Cash only.
ONVO' s Price/Net Cash Range Over the Past 10 Years
Min: 3.56  Med: 6.32 Max: 12.95
Current: 7.1
3.56
12.95
Price/Net Current Asset Value 6.87
ONVO's Price/Net Current Asset Value is ranked higher than
54% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.06 vs. ONVO: 6.87 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ONVO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.44  Med: 6.21 Max: 12.52
Current: 6.87
3.44
12.52
Price/Tangible Book 6.46
ONVO's Price/Tangible Book is ranked lower than
58% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. ONVO: 6.46 )
Ranked among companies with meaningful Price/Tangible Book only.
ONVO' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.22  Med: 5.93 Max: 12.36
Current: 6.46
3.22
12.36
Price/Median PS Value 0.66
ONVO's Price/Median PS Value is ranked higher than
81% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. ONVO: 0.66 )
Ranked among companies with meaningful Price/Median PS Value only.
ONVO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 0.82 Max: 3.28
Current: 0.66
0.26
3.28
Earnings Yield (Greenblatt) (%) -11.41
ONVO's Earnings Yield (Greenblatt) (%) is ranked lower than
65% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. ONVO: -11.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ONVO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -12.26  Med: 2.60 Max: 3.9
Current: -11.41
-12.26
3.9

More Statistics

Revenue (TTM) (Mil) $1.48
EPS (TTM) $ -0.42
Beta2.72
Short Percentage of Float12.45%
52-Week Range $1.60 - 4.35
Shares Outstanding (Mil)92.39
» More Articles for ONVO

Headlines

Articles On GuruFocus.com
2015 Must-Buys In Biotech Sector Feb 02 2015 
Why Organovo is A Safe Buy? Dec 18 2014 
Is Organovo A Safe Buy? Dec 08 2014 
This 3D Printing Company Is a Solid Long-Term Buy Jul 26 2014 
Why Organovo Is a Better Buy Than 3D Systems May 14 2014 
Dump 3D Systems and Buy Organovo May 09 2014 
Why Organovo Is The Only 3D Printing Company Worth Buying Apr 25 2014 

More From Other Websites
Organovo to Begin Trading on Nasdaq Stock Market Jul 26 2016
8:09 am Organovo to move its stock exchange listing to the NASDAQ Stock Market from the NYSE MKT... Jul 26 2016
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Jul 26 2016
Organovo to Begin Trading on Nasdaq Stock Market Jul 26 2016
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 20 2016
Organovo on Track to Commercialize Kidney Tissue; Company Signs First Customer Orders for Kidney... Jul 20 2016
This Deal Could Add Millions In Shareholder Value Jul 19 2016
Organovo Announces Release Date for Fiscal First-Quarter 2017 Financial Results Jul 14 2016
Organovo Announces Release Date for Fiscal First-Quarter 2017 Financial Results Jul 14 2016
Why Coherus Biosciences, Hortonworks and 3 Other Stocks Are Posting Big Gains Today Jul 11 2016
Organovo and Roche Researchers Publish Data Demonstrating Superiority of 3D Bioprinted Human Liver... Jul 11 2016
Organovo and Roche Researchers Publish Data Demonstrating Superiority of 3D Bioprinted Human Liver... Jul 11 2016
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jul 08 2016
ETF’s with exposure to Organovo Holdings, Inc. : July 5, 2016 Jul 05 2016
ETF’s with exposure to Organovo Holdings, Inc. : June 23, 2016 Jun 23 2016
Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q4, 2016 By the Numbers : June 22, 2016 Jun 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)